Table 2.
Tumour-associated antigens and corresponding CAR-Ts, ADCs or BiTEs
| Tumour-associated antigens (targets) | Biological function | Agent | Study phase | Research tumour type | Reference |
|---|---|---|---|---|---|
|
Tn-MUC1 Sialyl-Tn-MUC1 |
Alter cancer cell adhesion and motility | 5E5 CAR T | Mouse Model | Leukemia, PDAC, Breast cancer | 2016, Immunity |
| B7-H3 | T cell co-stimulatory molecule | B7-H3. CAR T | Patient derived xenograft | PDAC, Ovarian cancer, Neuroblastoma | 2019, Cancer Cell |
| Mesothelin | Tumour local invasion and metastasis | MSLN CARs | Phase I |
Mesothelioma, Ovarian carcinoma, PDAC |
NCT02159716 |
| Anetumab ravtansine | Phase I |
Mesothelioma, Ovarian carcinoma, PDAC, etc |
NCT03102320 | ||
| CEA | Tumour surface biomarker | CEA-CAR-T | Mouse models | Colorectal cancer, Gastric cancer, PDAC | 2019, Cancer Medicine |
| Phase II/III | PDAC | NCT04037241 | |||
| Mesothelin & CEA | dCAR-T | Cell models | PDAC | 2018, Journal of Hematology and Oncology | |
|
KRAS G12D HLA-C*08:02 |
Tumour formation and progression | CTL targeting KRAS G12D | Phase II | Metastatic cancers (Colorectal cancer, Glioblastoma, PDAC, Ovarian cancer, Breast cancer) |
2016, New England Journal of Medicine |
| HER2/ERBB2 | Tumorigenesis and tumour proliferation | Switchable CAR T against HER2 | Xenograft model | PDAC | 2019, Gut |
| CART-HER2 | Phase I | Biliary tract cancer, PDAC | NCT01935843 | ||
| DS-8201a | Phase I | Solid tumors | 2016, Clinical Cancer Research | ||
| CD133 | Tumour stem cells marker | CAR T-133 | Phase I | Hepatocellular carcinoma, Colorectal carcinoma, PDAC | NCT02541370 |
| PD-1 | Immune checkpoint | chPD1 T cells | Mouse model | Solid tumors (melanoma, renal cancer, liver cancer, PDAC, etc.) | 2020, Immunology |
| MUC16 | Tumour surface biomarker | DMUC5754A | Phase I | Ovarian cancer, PDAC | NCT01335958 |
| Guanylyl cyclase C | Membrane receptor | MLN0624 | Phase II | PDAC | NCT02202785 |
| Glypican-1 | Cell surface proteoglycan | GPC-1-ADC | Patient derived xenograft | PDAC | 2020, British Journal of Cancer |
| EpCAM | Cell adhesion | MT110 | Phase I | Colorectal cancer, Ovarian cancer, Gastric cancer, Lung cancer, Prostate cancer | NCT00635596 |
PDAC pancreatic ductal adenocarcinoma; CAR-T chimeric antigen receptor T cells; ADC antibody-drug conjugate; BiTE bispecific T-cell engager; MSLN Mesothelin; CTL cytotoxic T lymphocytes; PD-1 programmed death-1 receptor